CAMP4 Therapeutics Corporation (CAMP) is a Biotechnology company in the Healthcare sector, currently trading at $4.59. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is CAMP = $11 (+148.4% upside).
Valuation: CAMP trades at a trailing Price-to-Earnings (P/E) of -3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.42.
Financials: revenue is $3M, +100%/yr average growth. Net income is $80M (loss), growing at -65.9%/yr. Net profit margin is -2298.5% (negative). Gross margin is 53.1% (+16.1 pp trend).
Balance sheet: total debt is $2M against $48M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 7.35 (strong liquidity). Debt-to-assets is 1.7%. Total assets: $118M.
Analyst outlook: 16 / 24 analysts rate CAMP as buy (67%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 73/100 (Pass), Income 10/100 (Fail).
